Unveiling the potential of galectin-3 as a diagnostic biomarker for pancreatic cancer: a review.

biomakers galectin-3 pancreatic cancer

Journal

Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 12 06 2023
accepted: 17 09 2023
medline: 2 11 2023
pubmed: 2 11 2023
entrez: 2 11 2023
Statut: epublish

Résumé

Early detection of pancreatic cancer is crucial for improving patient outcomes, and identifying reliable biomarkers is a critical research area in this field. Galectin-3 (Gal-3) is a promising candidate for utilisation as a diagnostic biomarker in early-stage pancreatic cancer. This review aims to explore the potential of Gal-3 in pancreatic cancer diagnosis and its implications for precision medicine. Rigorous validation studies are essential to establish the clinical utility of Gal-3, including large-scale investigations to assess its sensitivity, specificity, and predictive value. Combining Gal-3 with existing biomarkers and advanced imaging techniques may enhance the accuracy of early detection. Moreover, Gal-3 holds promise for risk stratification, enabling the identification of high-risk individuals who could benefit from intensified surveillance and early interventions. However, challenges in standardised testing protocols, establishing reference ranges, assay reliability, workflow integration, cost-effectiveness, and healthcare provider education must be addressed for successful implementation. Despite these challenges, Gal-3 presents significant implications for precision medicine in pancreatic cancer management. By unravelling its potential and overcoming the hurdles, Gal-3 could revolutionise early detection, risk stratification, and personalised approaches in pancreatic cancer care. Collaborative efforts and continued research will be crucial in harnessing the full potential of Gal-3 as a diagnostic biomarker for early-stage pancreatic cancer.

Identifiants

pubmed: 37915694
doi: 10.1097/MS9.0000000000001363
pii: AMSU-D-23-01281
pmc: PMC10617888
doi:

Types de publication

Journal Article

Langues

eng

Pagination

5557-5567

Informations de copyright

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

Déclaration de conflit d'intérêts

All authors declare no conflicts of interest.

Références

Br J Cancer. 2018 Jan;118(1):52-61
pubmed: 29136404
Cancer Cell Int. 2019 Nov 21;19:309
pubmed: 31832021
BMJ Open Gastroenterol. 2020 May;7(1):
pubmed: 32414753
Nestle Nutr Inst Workshop Ser. 2016;84:91-102
pubmed: 26764478
Chem Biol Interact. 2019 Aug 25;309:108724
pubmed: 31228468
PLoS One. 2011;6(6):e20859
pubmed: 21698183
Clin Med (Lond). 2009 Dec;9(6):539-43
pubmed: 20095294
Anticancer Res. 2017 Sep;37(9):4979-4986
pubmed: 28870921
Mol Biol Rep. 2021 Jan;48(1):807-815
pubmed: 33398681
Cells. 2021 Nov 05;10(11):
pubmed: 34831271
Nat Rev Mol Cell Biol. 2020 Dec;21(12):729-749
pubmed: 33087899
Biol Chem. 2020 Sep 25;401(10):1153-1165
pubmed: 32755098
J Cell Mol Med. 2020 Oct;24(19):11583-11591
pubmed: 32886424
J Med Assoc Thai. 2010 May;93(5):523-8
pubmed: 20524437
Cancer Res. 2021 Aug 1;81(15):4054-4065
pubmed: 34117030
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
Acta Cytol. 2014;58(3):281-7
pubmed: 24854395
Front Oncol. 2021 Dec 20;11:799025
pubmed: 34988027
J Crohns Colitis. 2016 May;10(5):593-606
pubmed: 26786981
PLoS One. 2012;7(8):e42699
pubmed: 22900040
J Mol Model. 2018 Sep 6;24(10):274
pubmed: 30191337
Biomark Res. 2014 Oct 22;2:19
pubmed: 25356314
Curr Opin Cell Biol. 2011 Aug;23(4):383-92
pubmed: 21616652
Clin Cancer Res. 2002 Aug;8(8):2570-5
pubmed: 12171885
J Gastrointest Surg. 2019 Apr;23(4):768-778
pubmed: 30706376
Stat Med. 2017 Jul 10;36(15):2347-2362
pubmed: 28276080
Cancer Lett. 2016 Oct 10;381(1):269-77
pubmed: 27461582
F1000Res. 2020 Sep 1;9:1078
pubmed: 33082935
J Cancer Res Clin Oncol. 2012 Jun;138(6):1035-43
pubmed: 22367363
Immunol Lett. 2021 May;233:57-67
pubmed: 33753135
World J Gastroenterol. 2021 Jul 14;27(26):4045-4087
pubmed: 34326612
N Am J Med Sci. 2012 Sep;4(9):429-34
pubmed: 23050259
Pathol Oncol Res. 2012 Apr;18(2):299-307
pubmed: 21910036
Diagnostics (Basel). 2020 Oct 24;10(11):
pubmed: 33114412
Oncol Lett. 2019 Feb;17(2):2057-2062
pubmed: 30675272
MethodsX. 2017 Mar 30;4:153-165
pubmed: 28417081
Front Immunol. 2022 Dec 08;13:1029560
pubmed: 36569887
Anticancer Res. 2007 Jul-Aug;27(4B):2289-96
pubmed: 17695516
Cell Death Dis. 2013 Aug 01;4:e753
pubmed: 23907467
Int J Clin Oncol. 2011 Aug;16(4):352-8
pubmed: 21327452
Front Oncol. 2016 May 13;6:109
pubmed: 27242953
Curr Health Sci J. 2017 Apr-Jun;43(2):132-136
pubmed: 30595868
Expert Rev Proteomics. 2017 Nov;14(11):1037-1053
pubmed: 28974114
Diabetes Care. 2019 Sep;42(9):1752-1759
pubmed: 31262951
Cancer Res. 2013 Oct 15;73(20):6359-74
pubmed: 24097820
Sci Rep. 2017 Mar 06;7:43927
pubmed: 28262838
Int J Cancer. 2011 Dec 15;129(12):2775-86
pubmed: 21448903
Oncogene. 2011 Jun 2;30(22):2514-25
pubmed: 21258405
Cancer Cell Int. 2022 Jun 28;22(1):220
pubmed: 35761336
PLoS One. 2014 Sep 25;9(9):e103482
pubmed: 25254965
Pancreatology. 2016 Jan-Feb;16(1):115-20
pubmed: 26613889
Expert Rev Mol Diagn. 2007 Jan;7(1):87-98
pubmed: 17187487
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188409
pubmed: 32827580
World J Gastrointest Oncol. 2021 Oct 15;13(10):1263-1287
pubmed: 34721766
Biochem Soc Trans. 2008 Dec;36(Pt 6):1472-7
pubmed: 19021578
Verh K Acad Geneeskd Belg. 1997;59(6):489-514
pubmed: 9543820
Med J Malaysia. 2003 Dec;58(5):667-72
pubmed: 15190651
J Gastrointest Oncol. 2011 Sep;2(3):168-74
pubmed: 22811847
Carbohydr Polym. 2019 Jan 15;204:111-123
pubmed: 30366522
Exp Biol Med (Maywood). 2015 Aug;240(8):1019-28
pubmed: 26142116
Front Oncol. 2016 May 23;6:127
pubmed: 27242966
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352
pubmed: 32300252
Mediators Inflamm. 2017;2017:9247574
pubmed: 28607536
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gastroenterology. 2018 Apr;154(5):1524-1537.e6
pubmed: 29274868
Front Immunol. 2020 Jun 30;11:1328
pubmed: 32695112
Int J Health Sci (Qassim). 2022 Mar-Apr;16(2):1-2
pubmed: 35300268
Biochem Biophys Res Commun. 2020 Jan 15;521(3):674-680
pubmed: 31685208
Cell. 2021 Mar 18;184(6):1415-1419
pubmed: 33740447
Nat Med. 2020 May;26(5):649
pubmed: 32405066

Auteurs

Nicholas Aderinto (N)

Department of Medicine and Surgery, Ladoke Akintola University of Technology. Ogbomoso, Oyo-State.

Muili O Abdulbasit (MO)

Department of Medicine and Surgery, Ladoke Akintola University of Technology. Ogbomoso, Oyo-State.

Deji Olatunji (D)

Department of Medicine and Surgery, University of Ilorin, Ilorin, Kwara State, Nigeria.

Mariam Edun (M)

Department of Medicine and Surgery, University of Ilorin, Ilorin, Kwara State, Nigeria.

Classifications MeSH